Century Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | — | — | — |
| SG&A Expense | $24.0M | $33.2M | $34.7M | $31.9M |
| Operating Income | $-17.3M | $-138.1M | $-146.5M | $-133.8M |
| Operating Margin | -15.8% | -2,096.5% | -6,556.9% | -2,574.2% |
| Interest Expense | — | — | $540.0K | $1.0M |
| Pretax Income | $-9.6M | $-124.8M | $-134.8M | $-130.8M |
| Income Tax Expense | $-68.0K | $1.8M | $1.9M | $91.0K |
| Net Income | $-9.6M | $-126.6M | $-136.7M | $-130.9M |
| Net Margin | -8.8% | -1,920.9% | -6,115.1% | -2,518.4% |
| EPS (Basic) | $-0.14 | $-1.61 | $-2.30 | $-2.27 |
| EPS (Diluted) | $-0.14 | $-1.61 | $-2.30 | $-2.96 |
| Shares Outstanding (Basic) | 86.6M | 78.6M | 59.3M | 57.8M |
| Shares Outstanding (Diluted) | 86.6M | 78.6M | 59.3M | 32.4M |
| Dividends Per Share | — | — | — | — |